XCUR News and Press, Exicure Inc. From 08/11/23

2023-08-11 16:17:21 ET Exicure press release ( NASDAQ: XCUR ): Q2 GAAP EPS of -$0.68. Cash, cash equivalents and restricted cash were $3.5 million as of June 30, 2023, as compared to $9.8 million as of December 31, 2022. The Company expects that its cash and cash equiv...

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...

2023-07-17 01:57:28 ET Exicure press release ( NASDAQ: XCUR ): Q1 GAAP EPS of -$0.70. Cash, cash equivalents and restricted cash were $11.2 million as of March 31, 2023, as compared to $9.8 million as of December 31, 2022. The company expects that its cash and cash equ...

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...

2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...

2023-07-14 08:34:41 ET EdtechX Holdings   ( NASDAQ: EDTX ) +68% . ARB IOT Group ( ARBB ) +48% . PainReform  ( PRFX ) +35% . Nutriband  ( NTRB ) +35% . Western Acquisition Ventures  ( WAVS ) +20% . Nik...

2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% .  Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...

2023-05-26 16:18:18 ET Exicure ( NASDAQ: XCUR ) said Friday that the company's board supports CEO Jung Sang Kim's view to continue exploring strategic alternatives for the company. "These efforts include the possible sale of certain of the company’s...

Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic...

2023-05-19 16:23:49 ET Exicure ( NASDAQ: XCUR ) said Friday it received a notice of non-compliance from Nasdaq for not filing its form 10-Q for the quarterly period ended March 31, 2023 on time. The company said is working diligently to complete its form 10-Q and intends to fi...